Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study.
Jean-Baptiste AssiéFlorian CrépinEmmanuel GrolleauAnthony CanellasMargaux GeierAude Grébert-ManuardiNabila AkkacheAldo RenaultPierre-Alexandre HaussMarielle SabatiniValentine BonnefoyAlexis CortotMarie WislezClément GauvainChristos ChouaidArnaud ScherpereelIsabelle MonnetPublished in: Cancers (2022)
Second-line and onward nivolumab is effective against MPM in real life but with less effectiveness in >70 years. Ancillary studies are needed to identify the predictive factors.